Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage a...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2019-03-01
|
Series: | Serbian Journal of Dermatology and Venereology |
Subjects: | |
Online Access: | https://doi.org/10.2478/sjdv-2019-0002 |
id |
doaj-74069b33f7c9439cbdd896c958e4f948 |
---|---|
record_format |
Article |
spelling |
doaj-74069b33f7c9439cbdd896c958e4f9482021-09-05T14:01:55ZengSciendoSerbian Journal of Dermatology and Venereology1821-09022406-06312019-03-01111131810.2478/sjdv-2019-0002sjdv-2019-0002Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris PatientsBeltammer Belkais0Gargoom Ali1Taeib Ghada2Duweb Gamal3Dermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaDermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaDermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaDermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaIntroduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage activation and release of various cytokins, such as interleukin 12 (IL-12) and IL-23. Recently a new biologic agent Ustekinumab has been used in the treatment of psoriasis. Our aim in this study was to assess the efficacy and tolerability of ustekinumab in moderate to severe psoriasis vulgaris and to observe and report any adverse reaction.https://doi.org/10.2478/sjdv-2019-0002psoriasisustekinumabdermatologic agentsbiological therapytreatment outcomelibya |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Beltammer Belkais Gargoom Ali Taeib Ghada Duweb Gamal |
spellingShingle |
Beltammer Belkais Gargoom Ali Taeib Ghada Duweb Gamal Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients Serbian Journal of Dermatology and Venereology psoriasis ustekinumab dermatologic agents biological therapy treatment outcome libya |
author_facet |
Beltammer Belkais Gargoom Ali Taeib Ghada Duweb Gamal |
author_sort |
Beltammer Belkais |
title |
Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients |
title_short |
Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients |
title_full |
Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients |
title_fullStr |
Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients |
title_full_unstemmed |
Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients |
title_sort |
use of ustekinumab in the treatment of libyan psoriasis vulgaris patients |
publisher |
Sciendo |
series |
Serbian Journal of Dermatology and Venereology |
issn |
1821-0902 2406-0631 |
publishDate |
2019-03-01 |
description |
Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage activation and release of various cytokins, such as interleukin 12 (IL-12) and IL-23. Recently a new biologic agent Ustekinumab has been used in the treatment of psoriasis. Our aim in this study was to assess the efficacy and tolerability of ustekinumab in moderate to severe psoriasis vulgaris and to observe and report any adverse reaction. |
topic |
psoriasis ustekinumab dermatologic agents biological therapy treatment outcome libya |
url |
https://doi.org/10.2478/sjdv-2019-0002 |
work_keys_str_mv |
AT beltammerbelkais useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients AT gargoomali useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients AT taeibghada useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients AT duwebgamal useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients |
_version_ |
1717809399480713216 |